Admin Core

管理核心

• 批准号: 10269640
• 负责人: Jean-Pierre J. Issa
• 金额: $ 38.72万
• 依托单位: CORIELL INSTITUTE FOR MEDICAL RESEARCH
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-16 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10269640
• 关键词: Address; Administrator; Advocate; Award; Cancer Prognosis; Clinic; Clinical; Clinical Trials; Collaborations; Communication; Complex; Consultations; Data; Decision Making; Development; Electronic Mail; Eligibility Determination; Ensure; Genomics; Government; Grant; Infrastructure; Institutes; Interdisciplinary Study; Laboratories; Leadership; Malignant Neoplasms; Medical Research; Minority; Monitor; National Cancer Institute; Outcome; Pathology; Patients; Policies; Preparation; Progress Reports; Protocols documentation; Publications; Quality Control; Regulation; Reporting; Research; Research Activity; Research Infrastructure; Research Personnel; Research Project Grants; Resource Sharing; Strategic Planning; Supervision; Therapeutic Studies; Time; Translational Research; United States National Institutes of Health; Woman; Work; base; cancer care; cancer therapy; career; clinical research site; data sharing; design; epigenetic therapy; experience; improved; interdisciplinary collaboration; lectures; meetings; novel; novel therapeutic intervention; programs; quality assurance; recruit; screening; success; symposium; web site

PROJECT SUMMARY The Administrative Core will provide essential support to the Coriell Institute for Medical Research (Coriell) and Van Andel Institute (VAI) Epigenetic Therapy SPORE PIs and investigators to maximize success. It will be co- directed by Drs. Jean-Pierre Issa, Stephen Baylin, and Peter Jones, who co-chair the Executive Committee and provide overall supervision of three Projects, two additional Cores, Developmental Research (DRP) and Career Enhancement (CEP) Programs, and scientific direction of the SPORE. The Core Co-Directors will rely on the extensive broad-based scientific, research, and SPORE experience of the Internal and External Advisory Boards in critical decision making. An oversight committee consisting of the SPORE PIs and three clinical experts from the VAI-SU2C team (Drs. Rudin, El-Khoueiry and O’Connell) will ensure prioritization of SPORE trials within the VAI-SU2C team and at clinical sites. Success of the complex interdisciplinary research in the SPORE depends on integration of diverse epigenetic therapy research approaches. The Core will overcome barriers to interdisciplinary collaboration and data sharing and will ensure a unified translational research effort. The SPORE will be founded on planning, integration, and translational research efforts supported by this Core. Its leadership and staff will be responsible for monitoring/planning scientific activities; providing scientific direction; ensuring emphasis on translational research; ensuring interdisciplinary and inter-SPORE integration with major epigenetic therapy programs within/outside Coriell and VAI and other broad translational research activities; and providing optimal administrative and fiscal management. Specific responsibilities of the Core are: oversee and monitor all SPORE activities; promote integration and communication among the SPORE-related clinical programs; monitor the scientific integrity of all projects, and grant awards; assure compliance with institutional, governmental, and National Cancer Institute regulations; oversee the fiscal and budgetary activities of the SPORE; coordinate data control quality assurance issues; coordinate activities associated with clinical trials, including design of protocols, approval by regulatory bodies, implementation, and eligibility screening and assignment of patients to different studies; provide oversight and support for the shared Resources Cores; coordinate and manage meetings of the SPORE Oversight Committee, Executive Committee, Internal and External Advisory Boards, investigator meetings, research meetings, lectures, and symposia; administer the DRP and the CEP; coordinate interdisciplinary and inter-SPORE interactions and exchanges/meetings with other Epigenetic Therapy SPORE programs and investigators, and other SPORE programs; administer the activities of the Patient Advocates; comply with, and improve policies addressing recruitment and retention of women and minorities; and maintain a Epigenetic Therapy SPORE website focused on issues in epigenetic therapy translational research in cancers.

项目摘要 行政核心将为科里尔医学研究所（Coriell）和 Van Andel Institute（VAI）表观遗传疗法孢子和研究人员，以最大程度地提高成功。这将是共同的 由Drs执导。让·皮埃尔·伊萨（Jean-Pierre Issa），斯蒂芬·贝林（Stephen Baylin）和彼得·琼斯（Peter Jones），执行委员会联合主席， 提供三个项目，两个核心，发展研究（DRP）和职业的总体监督 增强程序（CEP）程序和孢子的科学方向。核心联合导演将依靠 内部和外部咨询委员会的广泛基于广泛的科学，研究和孢子经验 在关键决策中。一个由孢子PI和三名临床专家组成的监督委员会 VAI-SU2C团队（Rudin博士，El-Khoueiry和O'Connell）将确保优先考虑孢子试验 VAI-SU2C团队和临床站点。复杂的跨学科研究的成功取决于 关于潜水员表观遗传疗法研究方法的整合。核心将克服障碍 跨学科的合作和数据共享，将确保统一的翻译研究工作。孢子 将基于该核心支持的计划，集成和翻译研究工作。它的领导 员工将负责监视/规划科学活动；提供科学方向；确保 强调翻译研究；确保与主要表观遗传学 Coriell和Vai外部/外部的治疗计划以及其他广泛的转化研究活动；并提供 最佳的行政和财政管理。核心的特定职责是：监督和监视所有 孢子活动；促进与孢子有关的临床计划之间的整合和沟通；监视器 所有项目的科学完整性和授予奖励；确保遵守机构，政府和 国家癌症研究所法规；监督孢子的财政和预算活动；协调数据 控制质量保证问题；协调与临床试验相关的活动，包括协议设计， 监管机构，实施以及对患者的资格筛查和分配给不同的批准 研究；为共享资源核心提供监督和支持；协调和管理会议 孢子监督委员会，执行委员会，内部和外部咨询委员会，调查员 会议，研究会议，讲座和专题讨论会；管理DRP和CEP；协调 跨学科和跨学科的相互作用以及与其他表观遗传疗法孢子的交流/会议 计划和调查人员以及其他孢子计划；管理患者拥护者的活动； 遵守并改善解决妇女和少数民族招募和保留的政策；并保持 一个表观遗传疗法的孢子网站，重点介绍了表观遗传疗法转化研究的问题。